using recombinant PARP1 enzyme assay that resulted in the acquisition of three PARP1 inhibitors: 3 (IC50 = 12 μM), 4 (IC50 = 5.8 μM), and 10 (IC50 = 0.88 μM). Compound 4 (2,3-dihydro-1,4-benzodioxine-5-carboxamide) was selected as a lead and it was subjected to further chemical modifications, involving analogue synthesis and scaffold hopping. These efforts led to the identification of (Z)-2-(4-hydroxy
聚(
ADP-
核糖)聚合酶 1 (PARP1) 是一种广泛探索的抗癌药物靶点,在单链 DNA 断裂修复过程中发挥着重要作用。使用 PARP1-
苯并咪唑-4-甲酰胺晶体结构和药效团模型对 Maybridge 小分子文库进行高通量虚拟筛选 (HTVS),鉴定出 11 种化合物。使用
重组 PARP1 酶测定法评估这些化合物,从而获得三种 PARP1
抑制剂:3 (IC 50 = 12 μM)、4 (IC 50 = 5.8 μM) 和10 (IC 50 = 0.88 μM)。化合物4(2,3-dihydro-1,4-benzodioxine-5-carboxamide) 被选为先导化合物,并对其进行了进一步的
化学修饰,包括类似物合成和支架跳跃。这些努力导致了 ( Z )-2-(4-hydroxybenzylidene)-3-oxo-3,4-dihydro-2 H - benzo[ b ][1,4]o